DGAP-News
Evotec and Almirall enter into a multi-target alliance in medical dermatology
DGAP-News: Evotec SE / Key word(s): Miscellaneous |
- THE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS BASAL CELL CARCINOMA
- THE COLLABORATION LEVERAGES EVOTEC’S DATA-DRIVEN EVOIR&D PLATFORM FOR INTEGRATED DISCOVERY AND DEVELOPMENT OF FIRST-IN-CLASS THERAPIES AND ALMIRALL’S EXPERTISE IN MEDICAL DERMATOLOGY
Hamburg, Germany, and Barcelona Spain, 19 May 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Almirall S.A. (ALM), a global biopharmaceutical company focused on skin health, announced today a
multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as
atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.
The alliance will leverage Evotec’s fully integrated multimodality platform and combine it with Almirall’s leading expertise in Medical Dermatology. Both partners will contribute drug targets in
the research process. Leveraging the Company’s end-to-end integrated, AI/ML-driven EVOiR&D platform, Evotec will be responsible for drug discovery and pre-clinical development.
Almirall will lead the clinical development and marketing.
Under the agreement, Evotec receives an undisclosed upfront payment, research payments, as well as success-based milestones of potentially up to € 230 m per programme and royalties on net sales
in the high single-digit percentage range.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are very happy to enter this collaboration with Almirall, one of the leaders in the field of Medical Dermatology. The
collaboration has the potential to deliver superior first-in-class therapeutic options for many patients suffering from severe skin diseases such as atopic dermatitis or basal cell carcinoma. We
are looking forward to leveraging the complementary expertise of Evotec and Almirall in order to develop promising new drug candidates.”